Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Novacyt ( (FR:ALNOV) ).
Novacyt S.A. has provided an update on its liquidity agreement with Invest Securities SA, detailing the trading of its ordinary shares during August 2025. The company reported that 26,541 shares were purchased and 30,020 shares were sold under the agreement. The total number of ordinary shares in the company is 70,626,248, which shareholders can use for calculations regarding their interests. The liquidity agreement, governed by French law, allows Invest Securities to purchase shares on behalf of Novacyt, with shareholder approval for purchases up to a maximum price of €5.00 per share.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, with a primary focus on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation, providing solutions across human health, animal health, and environmental sectors. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, and has a commercial presence in over 65 countries.
See more data about ALNOV stock on TipRanks’ Stock Analysis page.